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Recombinant factor VIIa to treat severe bleeding in patients with
liver disease: Pitfalls and possibilities
Letters to the EditorTo the Editor:
Patients with liver disease frequently develop substantial
changes in their hemostatic system [1]. Recent laboratory and
clinical data are compatible with the concept of rebalanced
hemostasis in liver disease [2]. According to this concept, the
average patient with liver disease is in hemostatic balance due
to a concomitant decrease in pro- and anticoagulant pathways.
The hemostatic balance in patients with liver disease, however,
is much more fragile as compared to the hemostatic balance in
healthy individuals. Consequently, patients with liver disease
are at risk for both bleeding and thrombosis when the balance
is disturbed. Unfortunately, there is currently no clinical or labo-
ratory test able to predict whether a patient with liver disease is
at risk for either bleeding or thrombosis.
In a recent commentary in the section ‘‘International Hepatol-
ogy’’ of this Journal, Thabut and coworkers address the question
whether administration of recombinant factor VIIa (NovoSeven,
rFVIIa) to patients with liver disease poses them at an increased
risk for thrombotic complications [3]. The authors conclude that
the use of rFVIIa to patients with uncontrollable bleeding may be
justiﬁed, and potential thrombotic events should be considered
as ‘collateral damage’. Here, we aim to comment on the use of
rFVIIa in patients with liver disease to better appreciate the
risk-beneﬁt ratio in different clinical scenarios.
Current clinical data do not support prophylactic administra-
tion of rFVIIa to prevent excessive bleeding during surgical proce-
dures including partial hepatectomy and liver transplantation
[4,5]. Also, administration of rFVIIa to patients with variceal
bleeding is not indicated based on randomized controlled trials.950 Journal of Hepatology 2Although the average patient with liver disease is in hemo-
static balance, there are situations in which severe and uncon-
trollable bleeding does occur [1]. If the primary cause of
bleeding is not surgical and not primarily related to (excessive)
portal hypertension, administration of rFVIIa may be beneﬁcial,
which is supported by anecdotal reports [6,7]. The main advan-
tage of rFVIIa over other hemostatic therapies, such as blood
product infusion, is the low volume, which prevents ﬂuid over-
load and exacerbation of portal hypertension. In addition, trans-
fusion-related complications such as transfusion-related acute
lung injury and other transfusion reactions do not occur when
rFVIIa is administered.
The theoretical advantages of rFVIIa when used as a ‘‘rescue
agent’’ need to be balanced against a potentially increased risk
of thrombosis. We believe that clinical studies are required to
establish whether rFVIIa is truly effective in controlling bleeding
complications in patients with liver disease. Furthermore, we
believe it is important to realise which types of uncontrollable
bleeding might beneﬁt from rFVIIa administration, and in which
cases therapy with rFVIIa is likely futile.
The patients with uncontrollable bleeding that may beneﬁt
from rFVIIa are those patients in whom the bleeding complica-
tion is likely a result of an inadequate coagulation system. Exam-
ples of this are patients with massive hematomas, patients with
bleeding complications after small invasive procedures including
dental extraction, liver biopsy, paracenthesis and thoracenthesis,
and patients with bleeding complications during or after larger
invasive procedures. In the latter case, it should be excluded that
there is a surgical cause for the bleeding complication. Clinically,011 vol. 55 j 944–951
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a bleeding complication during surgery that is likely attributable
to inadequate hemostatic capacity is characterized by multiple
simultaneous bleeding sites, persistent oozing from a non-identi-
ﬁable source, or delayed bleeding following adequate hemostasis.
Patients that are theoretically unlikely to beneﬁt from rFVIIa are
patients with surgical bleeding, or bleeding complications that
are primarily related to pressure effects (such as variceal
bleeding).
In those patients with uncontrollable bleeding related to a
hemostatic defect, two factors may determine whether rFVIIa
might be effective in inducing hemostasis. Firstly, both in vitro
studies and clinical studies in trauma patients have established
a loss of hemostatic activity of rFVIIa with decreasing pH [8,9].
Patients with severe acidosis, which for example frequently
occurs in patients with acetaminophen-induced acute liver fail-
ure, may not beneﬁt from rFVIIa. Secondly, rFVIIa likely requires
a certain amount of residual endogenous coagulation factors.
rFVIIa is believed to exert its hemostatic effect by enhancement
of thrombin and ﬁbrin generation in either a tissue factor-depen-
dent or -independent manner [10]. For rFVIIa to enhance throm-
bin and ﬁbrin generation, a certain level of procoagulant proteins
(factors X, V, II, and ﬁbrinogen) will be required. In the patient
with liver disease, levels of these procoagulants are low, but gen-
erally sufﬁcient to support hemostasis. However, severe deﬁcien-
cies in procoagulants or ﬁbrinogen may occur in patients with
severe dilutional- or consumption coagulopathy (including
patients with severe sepsis and disseminated intravascular coag-
ulation and patients with uncontrolled bleeding). In such
patients, administration of rFVIIa may be futile.
In conclusion, there is a need for carefully designed clinical
studies to assess efﬁcacy of rFVIIa administration to patients with
liver disease and uncontrollable, hemostasis-related bleeding.
Only when these studies show a beneﬁcial effect of rFVIIa, an
increased risk of thrombotic events may be considered acceptable
‘collateral damage’. For now,webelieve there is little evidence for a
widespread use of rFVIIa as a rescue agent in patients with liver
disease.
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